GE Health­care launches MR con­trast agent in Korea

BioSpectrum (Asia) - - Supplier News -

GE Health­care Korea re­cently an­nounced the launch of Clar­iscan (gado­teric acid), a new macro­cyclic MRI con­trast agent, in Korea. Clar­iscan is a gadolin­ium-based con­trast agent (GBCA) de­signed to sup­port ef­fec­tive vi­su­al­iza­tion of ab­nor­mal­i­ties in the brain, spine and as­so­ci­ated tis­sues. As a macro­cyclic and ionic GBCA, Clar­iscan is known to be a gold-stan­dard de­tec­tion tool in MR imag­ing, of­fer­ing im­proved con­trast be­tween nor­mal and patho­log­i­cal tis­sue to en­able rapid de­tec­tion of ab­nor­mal­i­ties. Clar­iscan is the lat­est in a line of prod­ucts and ser­vices, in­clud­ing MRI, X-ray/CT and ul­tra­sound modal­i­ties pro­vided by GE Health­care to the ra­di­ol­ogy pro­fes­sion for over 30 years and it is avail­able at a range of doses in vials and pre-filled sy­ringes. Clar­iscan will be added to the fam­ily of GE con­trast me­dia and imag­ing prod­ucts along­side its ex­ist­ing lin­ear agent for MRI, Om­nis­can, which has been used in rou­tine di­ag­nos­tic prac­tice for over 25 years with over 80 mil­lion ad­min­is­tra­tions.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.